Loading
Led the FOLFIRINOX trials that gave pancreatic cancer its most active chemotherapy in both metastatic and adjuvant settings.
Thierry Conroy (Nancy, France) was principal investigator of PRODIGE 4/ACCORD 11, which showed FOLFIRINOX nearly doubles survival versus gemcitabine in metastatic pancreatic cancer, and of PRODIGE 24, which showed modified FOLFIRINOX after resection extends median survival to more than four years. These two trials define modern pancreatic cancer chemotherapy. He continues to lead PRODIGE GI trials.
This is the European standard the UK and NHS page for pancreatic cancer is compared against; NICE guideline NG85 (2018) covers the same ground with an older evidence base and a narrower set of funded drugs.
The best survival ever recorded in a pancreatic cancer trial, and the benchmark every perioperative trial (PREOPANC-3, Alliance A021806) and every adjuvant RAS inhibitor or vaccine trial (RASolute 304, IMCODE003) now has to beat or add to.
The second total neoadjuvant therapy schedule to change practice, and the one that shows the advantage is partly deliverability: chemotherapy given before an operation is completed by far more patients than chemotherapy given after one.
The document that made biomarker testing part of routine pancreatic cancer care in the United States; the 2018 version it built on fixed the second-line chemotherapy sequence still used in most guidelines.
Modified FOLFIRINOX is the adjuvant standard for patients who recover well from a pancreatic resection and can tolerate combination chemotherapy; gemcitabine-based regimens remain for those who cannot.
FOLFIRINOX and, soon after, gemcitabine plus nab-paclitaxel ended the era of single-agent gemcitabine for metastatic pancreatic cancer. The regimen's modified form later improved survival after surgery in PRODIGE 24, and its toxicity is why fitness, not just stage, decides which treatment a patient is offered.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tags pancreatic, trialist.
Shares PRODIGE 24/CCTG PA6: adjuvant modified FOLFIRINOX versus gemcitabine after resection of pancreatic cancer, Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial, PRODIGE 24 / CCTG PA6, Resectable pancreatic ductal adenocarcinoma.
Shares the tags chemotherapy, trialist.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tags pancreatic, trialist.
Shares PRODIGE 24 / CCTG PA6, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic.
Shares PRODIGE 24 / CCTG PA6, Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pancreatic.
Shares Pancreatic ductal adenocarcinoma and the tags pancreatic, trialist.
Shares Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic.